Catalyst Pharmaceuticals settles FIRDAPSE patent dispute with Lupin
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
August 25, 2025 8:03 AM EDTAs Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035
CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (SERB) have entered into a Settlement Agreement (Agreement) with Lupin Ltd and Lupin Pharmaceuticals, Inc. (collectively, Lupin). This Agreement resolves the patent litigation brought by Catalyst and SERB in... More
